We are an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. We launched the iStent®, our first MIGS device, in the United States in 2012, our next-generation iStent inject® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, our proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. We are leveraging our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View Stock Information

Financials & Filings

Access our filings with the Securities and Exchange Commission (SEC) via the link below. These filings are also available at www.sec.gov.

View Financials & Filings

Events & Presentations

Access information about recent and upcoming investor events via the link below.

View Events & Presentations

Contact Investor Relations

Glaukos Corporation
229 Avenida Fabricante
San Clemente, CA 92672

Telephone: 949-481-0510
Fax: 949-367-9984
Email: investors@glaukos.com